BlossomHill Q2 Loss Widens; BH-30643 Advances, Balance Sheet Strengthens

BlossomHill Therapeutics (BLSM) reported a Q2 2026 net loss of $23.8 million versus $13.2 million a year ago. The company highlighted FDA Fast Track designation for BH-30643 in EGFR C797S-positive NSCLC and plans a Phase 2 trial in Q1 2027.